Pricing Log in Create free account

Annovis Bio, Inc. (ANVS) vs Metagenomi Therapeutics, Inc. (MGX)

Annovis Bio, Inc. and Metagenomi Therapeutics, Inc. are both Biotechnology companies. Annovis Bio, Inc. and Metagenomi Therapeutics, Inc. are of similar size ($28.6M and $27.6M). Annovis Bio, Inc. has the higher net margin (0.00% vs −689.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Annovis Bio, Inc. leads on 7 and Metagenomi Therapeutics, Inc. on 3.

Valuation

Metric ANVS MGX Biotechnology median
P/E n/m n/m 10.60
P/S n/m 1.94 9.40
P/B n/m 0.23 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.66 0.66
EV/Sales n/m (4.72) 9.02
Earnings yield (218.29%) (355.71%) (32.88%)
Free cash flow yield (140.87%) (325.47%) (23.13%)

Profitability

Metric ANVS MGX Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (741.58%) 0.00%
Net margin 0.00% (689.20%) 0.00%
Free cash flow margin 0.00% (632.67%) 0.00%
Return on equity (703.68%) (60.61%) (51.96%)
Return on assets (227.74%) (41.91%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANVS MGX Biotechnology median
Revenue growth (TTM) — (59.84%) 6.76%
EPS growth (last fiscal year) 39.39% 0.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ANVS MGX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.47 4.50 4.97
Net debt to EBITDA 0.66 1.71 1.01

Dividend

Metric ANVS MGX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ANVS MGX Biotechnology median
Market cap 28.55m 27.60m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack